New meningitis vaccine for kids shows promise in large trial

NCT ID NCT07505888

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Sinovac Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This Phase 3 trial tests a new meningococcal conjugate vaccine in 660 healthy children aged 2-6 years. The vaccine targets four strains (A, C, Y, W135) that cause meningitis. Participants receive one shot and provide blood samples to compare immune response with a licensed vaccine. Safety is monitored for 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: group ACYW135 meningococcal conjugate vaccine
What this could lead to: If successful, this could provide a safer, more effective vaccine option to protect young children against four types of meningococcal bacteria that cause meningitis.
What could go wrong: This is a Phase 3 trial, but results are not yet available. The new vaccine may not prove superior or even non-inferior to the existing vaccine, and rare side effects may only emerge after larger use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPIDEMIC MENINGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningitis meningococcal meningitis meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPIDEMIC MENINGITIS MENINGOCOCCAL VACCINES

Contacts and locations

Locations

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention

Nanning, Guangxi, 530028, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.